Supercharged T-Cells take on Hard-to-Treat cancers
NCT ID NCT07342738
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have no good treatment options left. Participants receive the engineered cells plus chemotherapy to prepare their immune system. The main goals are to check safety and see if tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TCR-T cells (engineered immune cells) plus chemotherapy drugs fludarabine and cyclophosphamide
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid tumors that have specific KRAS mutations and have run out of standard therapies.
- What could go wrong
- This is a very early, small trial (25 people) focused mainly on safety. The treatment may not shrink tumors or could cause serious side effects. Success is far from guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- Can a new drug shield nerves from Chemotherapy's side effects?
- A stitch in time: could a device make abdominal closure safer?
- Can your own immune cells beat advanced cancer?
- Can we predict chemo brain before it happens?
- Can a new immunotherapy combo outsmart advanced lung cancer?